Tag Archives: tricuspid insufficiency

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Sex-Related Differences in Clinical Outcomes after Transcatheter Tricuspid Valve Intervention

Sex-Related Differences in Clinical Outcomes after Transcatheter Tricuspid Valve Intervention

We are aware of sex related differences when it comes to comorbidities, physiopathology and disease evolution in patients with tricuspid regurgitation (TR).  TR is more prevalent among women, whereas among men, coronary artery disease is more prevalent, with worse left ventricular ejection fraction and 10-year survival rate. Transcatheter tricuspid valve intervention (TTVIs) has surged as

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade.  Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness.  The bicaval

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | TriCLASP, Evolution at 30 Days

Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low.  Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients. The TriCLASP included 74 patients

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | 1 Year Outcomes of Tricuspid Valve Repair with Cardioband: Feasibility Study

Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect. Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing

Tavi en pacientes com bajo flujo, bajo gradiente clásico

TRICENTO: Promising Results for Severe Tricuspid Valve Regurgitation

Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table.   Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices.  The TRICENTO has an

Estenosis aórtica moderada y disfunción ventricular ¿debería apurarse la indicación del recambio?

Treating Both Atrial Valves Improves Survival

Courtesy of Dr. Carlos Fava. There a few treatment options for tricuspid valve disease. It is practically limited to diuretics and surgery, is associated to high mortality and, generally, mitral regurgitation.  Developing the “edge-to-edge” strategy with MitraClip has been shown beneficial and, at present, there are studies that claim this technique could be greatly beneficial

Cambios fisiológicos y clínicos luego de reparar la tricúspide

Physiological and Clinical Changes After Tricuspid Repair

After the recent announcement by the US Food and Drug Administration (FDA) green-lighting transcatheter aortic valve replacement (TAVR) in patients across the whole spectrum, and given the advancements regarding devices already in the market (such as MitraClip) and a variety of pulmonary valves, there is only one territory left to conquer: the long forgotten tricuspid

Costo efectividad de la reparación endovascular y quirúrgica en aneurismas complejos

Impact of Edge to Edge Transcatheter Tricuspid Valve Repair

Reducing tricuspid regurgitation with transcatheter valve repair is associated to improved liver function, which is often ignored by many cardiologists. This is especially true in cases with deteriorated liver function prior valve repair. Instead, kidney function did not show any changes. Transcatheter tricuspid valve repair seems attractive especially in patients with liver failure. Edge to

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

Surgery to Improve Survival in Isolated Tricuspid Regurgitation

Patients with isolated tricuspid regurgitation (i.e., who have no associated left-sided valve disease) are frequently treated conservatively. In many cases, valve disease is highly symptomatic, even with the optimization of medical treatment; however, an invasive strategy is seldom proposed. The aim of this work was to measure the impact of surgery on isolated tricuspid regurgitation

Top